Balance Sheet
Accounts PayablesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsCurrent LeasesGoodwillGoodwill & IntangiblesIntangiblesInventoryLiabilities and Shareholders EquityLong-Term InvestmentsMinority InterestNon-Current AssetsNon-Current DebtOperating LeasesOther Accumulated ExpensesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)ReceivablesRetained EarningsShareholder's EquityShares OutstandingTotal Current LiabilitiesTotal DebtTotal LiabilitiesTotal Non-Current LiabilitiesTreasury Shares
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Cumberland Pharmaceuticals (CPIX) Total Liabilities (2016 - 2025)

Cumberland Pharmaceuticals' Total Liabilities history spans 16 years, with the latest figure at $52.3 million for Q4 2025.

  • For Q4 2025, Total Liabilities fell 1.43% year-over-year to $52.3 million; the TTM value through Dec 2025 reached $52.3 million, down 1.43%, while the annual FY2025 figure was $52.3 million, 1.43% down from the prior year.
  • Total Liabilities for Q4 2025 was $52.3 million at Cumberland Pharmaceuticals, up from $40.1 million in the prior quarter.
  • Across five years, Total Liabilities topped out at $57.0 million in Q4 2022 and bottomed at $40.1 million in Q3 2025.
  • The 5-year median for Total Liabilities is $52.3 million (2025), against an average of $49.1 million.
  • The largest annual shift saw Total Liabilities surged 36.06% in 2022 before it dropped 23.43% in 2025.
  • A 5-year view of Total Liabilities shows it stood at $41.9 million in 2021, then surged by 36.06% to $57.0 million in 2022, then decreased by 8.53% to $52.1 million in 2023, then rose by 1.81% to $53.0 million in 2024, then fell by 1.43% to $52.3 million in 2025.
  • Per Business Quant, the three most recent readings for CPIX's Total Liabilities are $52.3 million (Q4 2025), $40.1 million (Q3 2025), and $40.2 million (Q2 2025).